Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
9 Tips for Avoiding Tax Season Cyber Scams 
Celltrion just completed the phase 3 trial for its COVID-19 antibody treatment and it has shown very positive results. The biopharmaceutical company headquartered in Incheon, South Korea proves the efficacy of its treatment and full phase 3 results will follow before this month ends.
Outcome of phase 3 tests for the new COVID-19 antibody treatment
Celltrion said on Monday, June 14, that phase 3 of the clinical study for its Rekirona, yielded good results. This means that it was proven to be safe and effective after being tested with volunteer patients from 13 countries worldwide.
As per The Korea Herald, 1,315 patients took part in the third phase trial for Rekirona or CT-P59. The tests were conducted between the months of January and April of this year.
The South Korean biotech company stated that the treatment is effective and significantly reduced the recovery time and rate of progression for acute symptoms of COVID-19. Celltrion discovered through the phase 3 trial that the risk of cases progressing to a severe condition of coronavirus infection was reduced by 70%. In the high-risk group of patients, the progression rate to severe stage was said to have been cut by 72%.
What’s more, those treated with Celltrion’s Rekirona also showed significant results in recovery time as it was shortened. It was said that recovering from the disease was 4.7 to 4.9 days faster compared to others who used other treatments, Yonhap News Agency reported.
Most importantly, it was reported that the Celltrion COVID-19 antibody treatment did not show any serious adverse reaction. Only mild and temporary reactions were noted on the patients during the trial.
Celltrion’s shares surge after Celltrion’s phase 3 trial results were announced
Meanwhile, Pulse News reported that Celltrion’s shares increased by 5.08 percent to ₩279,000 or around $249.69 after the phase 3 test results for Rekirona were revealed. Celltrion Pharm, the company’s drug developing unit’s shares also went up by 12.54 percent to ₩156,200 while Celltrion Healthcare’s shares surged to 5.02 percent to ₩123,500.
In any case, Celltrion will now use the good results to seek marketing approval for the Covid-19 therapy in the U.S. The company will submit the documents to the U.S. Food and Drug Administration and the European Medicines Agency so it can be allowed to sell the treatment in the said regions.
